MedWatch

World’s most expensive drug approved to treat hemophilia at USD 3.5m a dose

Despite the high cost, one analyst thinks that CSL Behring’s Hemgenix, the drug that frees up patients from almost all previously needed infusions, could be successful.

Photo: Christoph Soeder/AP/Ritzau Scanpix

US regulators approved CSL Behring’s hemophilia B gene therapy, a one-off infusion that frees patients from regular treatments but costs USD 3.5m a dose, making it the most expensive medicine in the world.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs